Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of ...

Morgan Stanley analyst Sarita Kapila initiated coverage of AstraZeneca (AZN) with an Overweight rating and 14,500 GBp price target The firm ...

National Institutes of Health (NIH) scientists and their colleagues report that a single dose of a broadly neutralizing antibody (bnAb) administered prior to virus exposure protects macaques from ...

Welcome, ladies and gentlemen, to AstraZeneca's full-year and Q4 2024 results conference call for investors and analysts. Before I hand over to AstraZeneca, I'd like to read the safe harbor statement.

AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of ...

British pharmaceutical giant AstraZeneca reported on Thursday a pre-tax profit of $1.666 billion for the fourth quarter, an 86% increase from $897 million in the same quarter the previous year. This ...

AstraZeneca has been approached a couple of times by Chinese authorities about their investigation into the drugmaker's former senior executive Leon Wang and has provided information as needed, its ...

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue overhanging shares: an investigation of a top executive by authorities in China, one ...

Wall Street falls as Trump imposes tariffs, but not as badly as feared The threat of a punishing trade war sent Wall Street ...

HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, defined by cancer cells that possess hormone ...

The AstraZeneca PLC ADR AZN slipped 1.27% to $69.86 Monday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index COMP falling 1.20% to ...

AstraZeneca PLC closed 15.78% below its 52-week high of £133.88, which the company achieved on September 3rd.